2015
Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]
Paidas M, Frieling J, de Jongh J, Drenth H, Streisand J. Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]. Obstetrics And Gynecology 2015, 125: 52s. DOI: 10.1097/01.aog.0000463689.71574.8f.Peer-Reviewed Original ResearchEarly-onset preeclampsiaRecombinant human antithrombinPhase 3 trialPopulation pharmacokinetic modelingHuman antithrombinAntithrombin deficiencyPlasma antithrombinPharmacokinetic modelingHereditary antithrombin deficiencyPopulation pharmacokinetic modelAntithrombin activity levelsDifferent pharmacokinetic propertiesPrior human studiesExpectant managementPerinatal morbidityPregnant patientsLoading doseMaternal administrationPregnant womenContinuous infusionSimilar efficacyClinical studiesPleiotropic effectsAntithrombin treatmentDose selection
2009
Liver dysfunction in pregnancy: an important cause of maternal and perinatal morbidity and mortality in Pakistan
Hossain N, Shamsi T, Kuczynski E, Lockwood C, Paidas M. Liver dysfunction in pregnancy: an important cause of maternal and perinatal morbidity and mortality in Pakistan. Obstetric Medicine 2009, 2: 17-20. PMID: 27582800, PMCID: PMC4989777, DOI: 10.1258/om.2008.080028.Peer-Reviewed Original ResearchFulminant hepatic failureLiver dysfunctionHepatitis EMaternal deathsPregnant womenStudy populationProspective observational study designAcute hepatitis EOverall perinatal mortalityUnderwent caesarean sectionAcute fatty liverAbnormal coagulation parametersCivil Hospital KarachiObservational study designHELLP syndromeHospital KarachiPerinatal morbidityPerinatal outcomesCaesarean sectionHepatic failureHepatitis A.Perinatal mortalityFatty liverThird trimesterSecond trimester